Patent · US Active

Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

US10640486B2 · kind B2 · utility

3Cited by

0References

13Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Sara Frattini · Castelleone, IT
Remko Alexander BAKKER · Biberach an der Riß, DE
Riccardo Giovannini · Verona, IT
Giacomo Fossati · Lissone, IT
Dieter Hamprecht · Verona, IT
Iain Lingard · Monza, IT
Alexander Pautsch · Ulm, DE
Bernd Wellenzohn · Friedrichshafen, DE

Key dates

Filing date	Oct 20, 2016
Grant date	May 5, 2020
Priority date	—
Expiry date	Oct 20, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2300/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds of general formula (I), wherein D1 to D3, -A-, n, R1, R2, Y1, L and y2 are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.